http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018115953-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81be82994243613df77c9362d0d7def6 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-20 |
| filingDate | 2017-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d92e0eb7f640038440ff28504c6e1df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d153700aa73e991ffee2b61af8c1bf43 |
| publicationDate | 2018-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2018115953-A1 |
| titleOfInvention | Methods and compositions for preventing or minimizing epithelial-mesenchymal transition |
| abstract | Compositions, including albumin compositions, which inhibit or reduce epithelial- mesenchymal transition (EMT) are described. In embodiments, such compositions comprise albumin and either i) no pro-EMT agent or a low concentration of pro-EMT agent; ii) a content of pro-EMT agent and anti-EMT agent in a ratio of pro-EMT agent : anti-EMT agent that is from 7:3 to 0:10; or iii) both. The pro-EMT agent is octanoic acid, octanoate salt or a combination thereof. The anti-EMT agent is a C9-C14 fatty acid, a salt of C9-C14 fatty acid, a monoglyceride of C9-C14 fatty acid, a diglyceride of C9-C14 fatty acid, a triglyceride of C9-C14 fatty acid, or a combination thereof. Use of such albumin compositions for various therapeutic applications based on albumin, and more particularly for the treatment of diseases or conditions in which EMT should be prevented or minimized. These albumin compositions can advantageously be used in combination with known active ingredients. Also, described are composition of an anti-EMT agent for use in the treatment of various therapeutic indications, and more particularly for the treatment of diseases or conditions where EMT should be prevented or minimized. |
| priorityDate | 2016-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 254.